Breast Cancer Clinical Trials in New York

Showing 41-60 of 838 trials

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

NCT06997029

The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.

Advanced Solid TumorAdvanced Breast CancerAdvanced Ovarian Cancer

Bristol-Myers Squibb234 participantsStarted Aug 2025

Birmingham, Alabama, United States • Fullerton, California, United States • Greenbrae, California, United States +18 more locations

RECRUITING< 1 mile

The PREDICT Registry:

NCT03448926

This is a prospective, non-interventional (observational) cohort study conducted within the medical network of the participating investigators and institutions. Patients meeting the eligibility criteria (see below) will be eligible for participation and the investigators will obtain written informed consent. A central Institutional Review Board (IRB), WCG IRB, will approve the protocol and each participating institution.

DCISStage 0 Breast CancerDuctal Breast Carcinoma In Situ

PreludeDx3,000 participantsStarted Feb 2018

Scottsdale, Arizona, United States • La Jolla, California, United States • San Mateo, California, United States +27 more locations

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

The PREDICT Registry:

Breast Cancer Trials in Other Cities

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer

Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

A Study of Meaning-Centered Therapy for Mexican Adults With Advanced Cancer

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

A Study of XMT-1660 in Participants With Solid Tumors

Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

PF-07104091 as a Single Agent and in Combination Therapy

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

GEN1047 for Solid Tumors - First in Human (FIH) Trial

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions

Other Conditions in New York